Generic drug of the therapeutic class: Gastro-Entero-Hepatology
active ingredients: Betamethasone
laboratory: Sigma Tau (Italy)
Box of 1 plastic bag with 100 ml cannula
· Hemorrhagic rectocolitis;
· Crohn's disease.
Dosage BETNESOL 5 mg Rectal solution Box of 1 plastic bag with 100 ml cannula
Treatment of the thrust: an enema per day.
The average duration of a cure is 15 to 20 days.
Maintenance treatment: 4 to 6 enemas per month.
Betnesol rectal solute is ready for immediate use.
The administration will preferably be done at bedtime to keep the enema as long as possible.
The patient lying on his side gently introduces into the anus the previously lubricated cannula by penetrating it to half of its length.
Then the patient gradually wraps the pocket on itself; the passage in the rectum of the solution it contains is thus carried out in about 1 to 2 minutes.
When the operation is over, the patient goes to bed for 3 to 5 minutes and then returns to his usual position of sleep seeking.
These are those of the general corticotherapy; in particular:
· Infections or fungal infections not controlled by a specific treatment;
· Some viruses in evolution, including herpes and shingles with ocular manifestations;
· Evolutionary gastric or duodenal ulcer
· Psychotic states;
· Alcoholic cirrhosis with ascites;
· Acute hepatitis virus A, B, or non-A;
· Hypersensitivity to any of the ingredients mentioned in the Composition section.
Betnesol side effects
Betnesol rectal solute is usually well tolerated. In case of prolonged treatment or high dosage, monitor the possible occurrence of clinical signs of hypercorticism, indicating absorption of the product by the eroded mucosa.
In addition, discomfort or slight pain may appear at the beginning of treatment during the administration of the product.
Reporting of suspected adverse reactions
The reporting of suspected adverse reactions after authorization of the drug is important. It allows continuous monitoring of the benefit / risk ratio of the drug. Health professionals must report any suspected adverse reactions via the national reporting system: National Agency for the Safety of Medicines and Health Products (Ansm) and the network of Regional Pharmacovigilance Centers. Website: www.ansm.sante.fr.